- Japan
- /
- Medical Equipment
- /
- TSE:6523
There Is A Reason PHC Holdings Corporation's (TSE:6523) Price Is Undemanding
When you see that almost half of the companies in the Medical Equipment industry in Japan have price-to-sales ratios (or "P/S") above 1.8x, PHC Holdings Corporation (TSE:6523) looks to be giving off some buy signals with its 0.4x P/S ratio. However, the P/S might be low for a reason and it requires further investigation to determine if it's justified.
Check out our latest analysis for PHC Holdings
What Does PHC Holdings' Recent Performance Look Like?
With revenue growth that's inferior to most other companies of late, PHC Holdings has been relatively sluggish. The P/S ratio is probably low because investors think this lacklustre revenue performance isn't going to get any better. If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.
Keen to find out how analysts think PHC Holdings' future stacks up against the industry? In that case, our free report is a great place to start.Is There Any Revenue Growth Forecasted For PHC Holdings?
There's an inherent assumption that a company should underperform the industry for P/S ratios like PHC Holdings' to be considered reasonable.
Taking a look back first, we see that there was hardly any revenue growth to speak of for the company over the past year. Still, the latest three year period was better as it's delivered a decent 5.6% overall rise in revenue. Therefore, it's fair to say that revenue growth has been inconsistent recently for the company.
Shifting to the future, estimates from the six analysts covering the company suggest revenue should grow by 1.8% per annum over the next three years. With the industry predicted to deliver 5.8% growth each year, the company is positioned for a weaker revenue result.
In light of this, it's understandable that PHC Holdings' P/S sits below the majority of other companies. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.
The Bottom Line On PHC Holdings' P/S
Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.
As we suspected, our examination of PHC Holdings' analyst forecasts revealed that its inferior revenue outlook is contributing to its low P/S. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.
Before you settle on your opinion, we've discovered 2 warning signs for PHC Holdings (1 is a bit unpleasant!) that you should be aware of.
If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:6523
PHC Holdings
Through its subsidiaries, provides medical devices, healthcare IT solutions, and life science products and services primarily in Japan.
Undervalued average dividend payer.
Similar Companies
Market Insights
Community Narratives


